Fund Holdings — Caligan Partners LP

Total Portfolio Value
$296.52M
Total Bought
$82.78M
Total Sold
$9.07M
Net Transaction
+$73.72M
Filing Period:
Securities
▲▼
SharesValue ($K)
Q3 2023
▲▼
Q4 2023
▲▼
Change
▲▼
Q3 2023
▲▼
Q4 2023
▲▼
Weight (%)
▲▼
Change
▲▼
LIQUIDIA CORP(LQDA)9,243,62710,360,945+1,117,31858,605124,64242.03%+66,038
ALIMERA SCIENCES INC16,835,15416,835,154052,18972,72824.53%+20,539
AGIOS PHARMACEUTICALS INC(AGIO)4,833441,833+437,0001209,8403.32%+9,720
Y-MABS THERAPEUTICS INC23,3211,048,425+1,025,1041277,1502.41%+7,023
ANIKA THERAPEUTICS INC1,081,3601,081,360020,14624,5048.26%+4,358
EXELIXIS INC(EXEL)910,730910,730019,89921,8487.37%+1,949
VERONA PHARMA PLC183,064183,06402,9843,6391.23%+655
ADMA BIOLOGICS INC597,513473,087-124,4262,1392,1380.72%-1
SOCIETAL CDMO INC1,689,7681,689,76807945920.20%-202
VERRICA PHARMACEUTICALS INC(VRCA)259,5930-259,5931,0100—-1,010
EVOLUS INC(EOLS)1,683,8361,317,856-365,98015,39013,8774.68%-1,513
STANDARD BIOTOOLS INC(LAB)7,622,4137,042,413-580,00022,10515,5645.25%-6,541
Page 1 of 1
Caligan Partners LP — 13F Holdings — Q4 2023 | TickerTrail